It has been known for some time that colesevelam (Wel-Chol, Sankyo), a bile acid-binding resin indicated for lowering low-density lipoprotein-cholesterol (LDL-C) levels, reduces glucose levels in individuals with type-2 diabetes. Given that a proportion of this population cannot use generic metformin (Glucophage canadian, Bristol-Myers Squibb) because of elevated cre-atinine values, and given that another group [...]
Continue reading " American Diabetes Association: Colesevelam "































